Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

By Bak Ann Mosegaard   Egefjord Lærke   Gejl Michael   Steffensen Charlotte   Stecher Chalotte Willemann   Smidt Kamille   Brock Birgitte   Rungby Jørgen  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 10, 2011-10 ,pp. : 1153-1162

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs

By Mentlein Rolf  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 1, 2005-01 ,pp. : 57-64

Informa Healthcare

Access to resources Recommend Favorite

Incretin-Targeting Technologies for Type 2 Diabetes: Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 7, 2006-07 ,pp. : 3-7

Adis International

Access to resources Recommend Favorite

Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2

By Brubaker Patricia L   Anini Younes  

Canadian Journal of Physiology and Pharmacology, Vol. 81, Iss. 11, 2003-11 ,pp. : 1005-1012

NRC Research Press

Access to resources Recommend Favorite

Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection

By Hölscher Christian  

CNS Drugs, Vol. 26, Iss. 10, 2012-10 ,pp. : 871-882

Adis International

Access to resources Recommend Favorite